BRISBANE, Calif., Feb. 28, 2024 (Globe Newswire) — Vera Therapeutics, Inc. (NASDAQ: : VERA) announced today. Our management team announced that we will be participating in the 44th annual TD Cowen Healthcare Conference, starting March 4th.th up to 6th At the Marriott Copley Place in Boston, Massachusetts.
|
IgAN company panel discussion details: |
|
|
date: |
Monday, March 4thth |
|
time: |
9:10am (Eastern Standard Time) |
|
Bella representative: |
Dr. Robert Brenner, Chief Medical Officer |
|
Vera Therapeutics Fireside Chat Details: |
|
|
date: |
Monday, March 4thth |
|
time: |
2:10pm ET |
|
Presenter: |
Dr. Marshall Fordyce, Chief Executive Officer |
|
Webcast: |
https://wsw.com/webcast/cowen154/vera/2016052 |
A replay of the event will be available for viewing for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.
Management also participates in one-on-one investor meetings.
About Vera Therapeutics
Vera Therapeutics is a late-stage clinical biotechnology company focused on developing treatments for serious immune diseases. Vera's mission is to advance treatments that target the causes of immune diseases to change the standard of care for patients. Vera's lead product candidate is atacicept, a fusion protein self-administered once weekly as a subcutaneous injection that combines B cell activating factor (BAFF) and proliferation-inducing ligand (APRIL) to stimulate the production of autoantibodies in B cells and plasma cells. ). It causes certain autoimmune diseases such as IgAN, also known as Berger's disease, and lupus nephritis. Additionally, Vella is evaluating additional diseases in which atacicept's reduction of autoantibodies may prove medically useful. Vera also has MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain situations, such as kidney transplants. We are also developing. Vera retains all worldwide development and commercial rights to atacicept and his MAU868. For more information, please visit www.veratx.com.
For more information, please contact us below.
Investor contact information:
Joyce Allaire
Life science advisor
212-915-2569
jallaire@lifesciadvisors.com
Media contact:
Mali purpura
Life science advisor
mpurpura@lifesciadvisors.com
